Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
Venture report: Arch, Foresite $1B AI play Xaira starting with Baker lab’s de novo biologics. Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more
